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Chronic obstructive pulmonary disease (COPD) is a respiratory disease that results in airflow
limitation and respiratory distress. The effects of COPD, however, are not exclusively limited
to respiratory function and people with COPD face many non-respiratory manifestations that
affect both function and mobility. Deficits in function and mobility have been associated with
an increased risk for falling in older adults. The purpose of this study was to provide a theoret-
ical framework to identify risks factors for falls in people with COPD. We have analyzed the
literature to identify possible relationships between pathophysiological changes observed in
COPD and common risk factors for falls. Well-established fall risk factors in people with COPD
include lower limb muscle weakness and impaired activities of daily living. Other intrinsic risk
factors such as gait and balance deficits, nutritional depletion, malnutrition, depression,
cognitive impairments and medications are possible risk factors that need to be confirmed with
more studies. There is no evidence that visual deficits are common in COPD. The role that
precipitating factors such as syncope and postural hypotension may have on fall risk is unclear.
Exacerbations and dyspnea do not have a precipitating effect on fall risk but they contribute to
the progressive physical deterioration that may theoretically increase the risk for falls. While
these results suggest that people with COPD might have an increased susceptibility to fall
compared to their healthy peers, further research is needed to determine the prevalence of
falls and specific risk factors for falls in people living with COPD.
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tory disease characterized by progressive, partially
reversible airflow limitation, which results from an
emphysematous destruction of the lung parenchyma and
increased airway resistance due to inflammation, fibrosis,
bronchospasm and increased mucous production. Despite
being formerly considered a disease affecting the lungs, it
is now well recognized that people living with COPD also
suffer from many non-respiratory manifestations including
skeletal muscle dysfunction, systemic inflammation, nutri-
tional depletion and malnutrition.1e4 Cardiovascular prob-
lems (e.g., coronary artery disease),5 neurological
impairments (e.g., polyneuropathy),6e8 and metabolic
disorders (e.g., osteoporosis)9 are also commonly associ-
ated with COPD as are psychological alterations such as
depression and anxiety.10e13 While the presentation,
development and manifestation of COPD are highly variable
from patient to patient, the severity of the disease typi-
cally progresses as the patient ages.14 As such, ageing-
related physiological changes and co-morbidities may
compound the pathophysiological challenges generally
observed in patients with COPD.
Falls, which are common among older people, can have
devastating effects on overall function, health-related
quality of life (HRQoL) and life expectancy. Although
chronic conditions have been commonly associated with
a higher risk for falling,15 the potential implications of both
respiratory and non-respiratory manifestations of COPD on
the fall risk of these individuals have not been systemati-
cally examined. Furthermore, studies specifically analyzing
the prevalence of falls among people with COPD are lack-
ing. To date, only one fall-risk study has included people
diagnosed with COPD.16 In this large cross-sectional retro-
spective study (4050 older women), a linear trend of
increasing fall risk with increasing number of chronic
diseases was found (ORZ 1.37; 95% CI: 1.25,1.49). Moreimportantly, COPD was found to be one of the leading
conditions associated with number of falls, second only to
osteoarthritis. Because this study did not include neuro-
logical conditions commonly associated with high preva-
lence of falls such as stroke17 or Parkinson’s disease,18
whether people with COPD have an increased risk for falling
compared to these patients is currently unknown.
Recent research has highlighted the importance of iden-
tifying risk factors for falls in order to enhance prevention.19
Given the scarcity of studies specifically assessing contrib-
uting factors for falls in people with COPD, this review aims
to provide a theoretical framework to identify potential risk
factors that could increase fall incidence among these
individuals. We report the pathophysiological manifesta-
tions (i.e., respiratory and non-respiratory) commonly
observed in COPD and well-established risk factors for falls
to study any potential association. In an attempt to evaluate
the relevance of independent risk factors for falls in COPD,
the evidence behind each risk factor will be categorized into
three different levels: established, possible and theoretical.
The number of studies and their methodological quality will
determine the level of evidence. The clinical relevance of
this review lies in identifying specific risk factors for falls in
people with COPD, which may facilitate the design of
appropriate rehabilitation strategies to prevent falls.Risk factors for falls
To analyze the different aspects that can increase fall
occurrence in people with COPD, we propose the use of
a framework (Fig. 1) that includes intrinsic and precipi-
tating factors for falls.20 Intrinsic factors include those
related to the physical and psychological status of the
individual: muscle weakness, gait, balance, visual deficits,
use of an assistive device, impaired activities of daily living
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Figure 1 Theoretical framework with the risk factors for falls in people with COPD and potential interactions. Intrinsic and
precipitating factors are depicted by blank and shaded rectangles, respectively.
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tions are also considered an intrinsic factor due to their
inextricable impact on the physical and psychological well
being of the individual.22 In addition, nutritional depletion
and malnutrition, which are common in people with COPD,
are also included as potential intrinsic factors. Precipitating
factors are acute episodes (e.g., syncope and postural
hypotension)23,24 that might increase the risk for falls.
Exacerbations and dyspnea, which are common in COPD,
are also included as potential precipitating factors.
Although falls can also be affected by extrinsic factors such
as environmental hazards (e.g., stairs and poor lighting),
this framework only analyzes intrinsic and precipitating
factors that may increase fall risk in people with COPD. Due
to the ensuing multitude of possible risk factors for falls in
COPD, the proposed framework outlines potential interac-
tions among these factors (Fig. 1). This framework may
prove useful to identify potential risk factors for falls in
both clinical practice and research.
Intrinsic factors
Muscle weakness
Numerous clinical trials25,26 and systematic reviews27 have
shown strong correlations between fall incidence and lower
limb muscle weakness. Muscle strength is thought to be an
essential factor in maintaining postural control andminimizing postural sway,28,29 both of which are important
in preventing older people from falling.23 Muscle power,
which appears to be more closely related to postural
control (e.g., single-leg stand and postural sway)30 and
functional performance (e.g., stair climbing and comfort-
able gait speed)31e34 than muscle strength, might be even
more important to prevent falls.35,36
Muscle strength and endurance are reduced in people
with COPD compared to healthy controls. Lower limb
muscles, which are actively involved in fall avoidance
strategies, are preferentially impaired in these individ-
uals.37 For example, Mathur et al. found that a group of
people with moderate to severe COPD (FEV1Z 51 17%
predicted) had reduced volume (w25%), strength (w25%),
and increased fat infiltration (w30%) of the thigh muscles,
when compared to a healthy control group matched for
age, gender and body mass.38,39 All these factors (i.e.,
reduced muscle volume, strength and increased fat infil-
tration) have been associated with an increased loss of
function and mobility in older adults.40
Muscle endurance has found to be reduced in people with
COPD compared to healthy controls. For example, one study
assessed muscle endurance through a protocol in which
participants had to perform 100 sub-maximal knee exten-
sions.41 While the control group was able to complete the
protocol (i.e., 100 sub-maximal knee extensions), a large
percentage (w43%) of people with COPD were not able to
complete the protocol. Reduced muscle endurance in COPD
is important because it reflects increased muscle
1260 M. Roig et al.fatigability,42 which has been associated with impaired
postural control assessed by single-leg stand in young
adults.43,44 At the functional level, muscle activation
measured with magnetic stimulation has found to be signif-
icantly lower in severely deconditioned (FEV1Z 29 9%
predicted) peoplewith COPD compared to controls (89 20%
versus 109 6%; p< 0.01).45 Other common structural
muscle abnormalities in COPD also include muscle fibre
atrophy (most notably in fast twitch type II fibres), reduced
capillary density, mitochondrial dysfunction and lower
proportion of oxidative enzymes.46 Taken together these
abnormalities indicate an overall decline in both the
contractile and oxidative capacity of lower limb muscles in
people with COPD.47
Muscle power, defined as the product of force and
velocity of muscle contraction, has not been investigated
in people with COPD. However, given that strength and
power are so highly correlated,48 it is unlikely that people
with COPD, with compromised muscle strength, could
have normal values of muscle power. The preferential
atrophy of fast twitch type II fibres in the lower limb
muscles of these individuals49 is indicative of decreased
ability to perform activities involving fast and powerful
muscle contractions.50 Given the importance of muscle
function in the prevention of falls, it is possible that the
reductions of muscle strength, and presumably power, in
people with COPD could predispose this population to fall
(Table 1).
Gait deficits
Since falls are reported to occur mainly during walking
activities,51,52 it is not surprising that gait deficits had been
associated with disability and falls in older adults.53 Gait
deficits have been commonly assessed both quantitatively
(e.g., speed and distance) and qualitatively (e.g., gait
variability and instability). Quantitatively, gait speed has
usually been assessed by measuring the time required to
walk a number of meters (5e8 m) either at comfortable
(self-selected) or fast gait speeds.54 Lowered comfortable
gait speed (<1 m s1) measured over an 8 m walkway, has
found to be strongly associated with an increased risk for
falls (RRZ 5.4; 95% CI: 2.0,14.3) in seniors aged 75 years
old and older.55 Consistent with reduced gait speed, the
time required to walk 400 m has also shown to be signifi-
cantly larger in a group of fallers compared to non-fallers
(338 65.8s versus 330.5 60s; p< 0.05).56
Only a few studies have reported gait speed impairments
in people with COPD. For example, Butcher et al.57 repor-
ted that fast gait speeds measured over a 6-m walkway
were significantly lower (w28%) in oxygen-dependent
people with COPD (FEV1Z 29.9 3.7% predicted)
compared to a healthy control group. Although the values
obtained by this group of people with COPD
(1.53 0.11 m s1) are well above the threshold for fall risk
established in older adults (<1 m s1),55 it should be taken
into account that in this study,57 gait speed tests were
performed at fast, not comfortable gait speeds. Average
values of fast gait speed for healthy elderly (<60 years)
range from 0.84 m s1 to 2.1 m s1.54 Since normative data
on comfortable gait speed in people with COPD are not yet
available, more studies are required to establish averagemeasures of gait speed and specific values prognostic of an
increased fall risk in COPD.
Another quantitative approach commonly used to eval-
uate gait deficits consists of measuring walking distance.
Although walking distance is intrinsically related to gait
speed and stride length,58 the association between reduced
walking distance and increased fall risk in older adults has
not been directly investigated. Depending on the level of
impairment, walking distance tests such as the six-minute
walk test (6 MWT) or the shuttle walk test (SWT) provide
a good estimate of endurance/aerobic capacity59 and
overall functional performance.60 For example, walking
distance in the 6 MWT has been correlated to peak oxygen
consumption (rZ 0.63e0.79) in people with COPD61 and
measures of muscle function commonly associated with
increased fall risk such as strength (r2Z 0.38) and peak
power (r2Z 0.48) of lower limbs in older adults.62 Given
these associations, it is likely that lowered walking distance
might be correlated to increased fall risk.
Unlike gait speed, lowered walking distance has been
extensively reported in people with COPD.63 For example,
people with end-stage emphysema have shown a lower
6 MWT walking distance (235.1 92 m)64 compared to
reference data (w535 m) from healthy older adults (w61
years).65 While these studies indicate that gait impairments
are not uncommon in people with COPD, and therefore,
that increased fall risk associated with gait deficits might
be possible (Table 1), qualitative studies58 assessing gait
kinematics (e.g., variability and instability) associated with
fall risk in these individuals are lacking.
Balance deficits
Postural control is mainly determined by the interaction of
three major sensory systems: vestibular, somatosensory
and visual.66,67 Postural control is critical in preventing
older people from falling.20 A recent meta-analysis of 16
controlled studies ranked balance disorders as the second
most important individual risk factor for falling following
lower limb muscle weakness.68 Not surprisingly, balance
training has shown to be effective in lowering fall risk in
this population.69
Unlike walking distance and muscle strength, postural
control has not been extensively investigated in COPD. A
prospective cohort study investigating postural control in
people with COPD (FEV1Z 62 23% predicted) found
a significant reduced performance (9%; p< 0.0017) in the
Functional Reach Test when the COPD group (nZ 1202) was
compared with the control group (nZ 302).63 The Functional
Reach Test is a clinicalmeasure of balance thatmeasures how
far a subject can reach forward beyond arm’s length using
a fixed base of support (i.e., feet on the floor) without losing
balance.70 Another study showed significant lower scores in
the Community Balance and Mobility Scale in two groups of
people with moderate (FEV1Z 45.7 3.7% predicted) and
severe (FEV1Z 29.9 3.7% predicted) COPD compared to
ahealthy control group.57However, differencesamonggroups
in postural sway measured through dynamic posturography
were not significant. Chang and colleagues investigated
standing postural sway before and after a sub-maximal exer-
cise task (6 MWT) in a group of 19 people (69 9 years) with
COPD (FEV1Z 46% predicted).
71 Postural sway was
Table 1 Qualitative analysis of different evidence levels of intrinsic risk factors for falls in people with COPD. Evidence is categorized as established (E), possible (P) and
theoretical (T). A rationale to explain the different levels of evidence is provided.
Risk factor Evidence as risk
factor for falls
in older people
Rationale Evidence
in people
with COPD
Rationale
Muscle weakness
Strength E Deficits in muscle strength are associated with increased fall
risk. There are no studies reporting on muscle endurance and
power and their effect on fall risk. However, strength,
endurance and power are highly correlated
E Deficits in muscle strength and endurance are
common in people with COPD. Muscle power has not
been investigated in people with COPD but muscle
power is highly correlated with strength
Endurance P E
Power P P
Gait deficits
Speed E Lower gait speed has been associated with increased fall risk.
There are no studies reporting on walking distance and fall risk.
However, reduced walking distance and gait speed are correlated
P Only one study has are reported reduced gait speed
in people with COPD. Lower walking distance is
common in people with COPD
Distance P E
Balance deficits E Deficits in postural control are associated with increased fall risk P Only three studies have reported balance deficits in
people with COPD
Visual deficits E Visuals deficits are associated with increased fall risk T There are no studies reporting on visual deficits in
people with COPD but the use of corticosteroids in
people with COPD is common and their visual side-
effects are well established
Nutritional depletion
and malnutrition
P There are no studies reporting on nutritional depletion and
increased fall risk. However, some studies have reported
associations of muscle mass and vitamin D deficiency with
fall occurrence
E Nutritional depletion and malnutrition are common
in COPD. Nutritional depletion reduces muscle mass
and contributes to muscle weakness. Vitamin D
deficiency is common in people with COPD
Use of assistive
device
E The use of an assistive device is associated with increased fall
risk. However, the underlying mechanisms behind this
association are unknown
e The use of an assistive device is not frequent among
people with COPD compared to healthy peers
Impaired ADLs E Impaired ADLs are associated with increased fall risk E Impaired ADLs are common in people with COPD and
contribute to physical deterioration and reduced
mobility
Depression E Depression is associated with increased fall risk. However, the
underlying mechanisms behind this association are unknown
P Depression is common in people with COPD. However,
the exact prevalence is unknown
Cognitive
impairments
E Cognitive impairments are associated with increased fall risk P Cognitive impairments are common in people with
COPD. However, the exact prevalence is unknown
Medications (type)
Psychotropic E Psychotropic and cardiac drugs are associated with increased
fall risk. The side-effects of corticosteroid use on muscle
weakness and vision are well established
T The use of psychotropic and cardiac medications
might be high in people with COPD. However, the
exact prevalence is unknown. The use of
corticosteroids is common in people with COPD
Cardiac E T
Corticosteroids P P
Bronchodilators e e
Theophylline e e
Medications
(number)
E The number of medications is associated with increased fall risk E The use of multiple medications is common in
people with COPD
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1262 M. Roig et al.significantly increased after the 6 MWT, which suggests that,
as shown in other studies with healthy individuals,43,44 fatigue
may worsen postural control in patients with COPD. More
importantly, when compared to a fall-risk study that used
similar balance tests in 156 older adults (76.5 5.1 years),72
Chang et al. found that the values of lateral postural sway
measured at baseline in the COPD group were similar to those
with a history of falls. In spite of the small number of studies
assessing postural control in COPD, these preliminary results
suggest that increased fall risk secondary tobalancedeficits in
these individuals may be present (Table 1).
The underlying mechanisms for the increased postural
sway observed in people with COPD are currently unknown.
Although vestibular deficits are unlikely,73,74 somatosensory
deficits could contribute to impaired balance in this group.
For example, studies evaluating polyneuropathy in people
with COPD have shown that the presence of nerve
conduction abnormalities is not uncommon, especially in
the most disabled individuals. Appenzeller et al. reported
reduced peroneal nerve conduction velocity in people with
severe COPD.75 Another study revealed electrophysiological
disturbances in the motor and sensory nerves of 23 people
with severe COPD (FEV1< 50% predicted).
6 In a more recent
study, 5 out of 30 people with moderate COPD (FEV1< 80%
predicted) showed signs of axonal neuropathy (smaller
amplitude potentials, increased latency, decreased
conduction velocity) compared to an age-matched group8
but these anomalies were only significant in the afferent
nerves of the most impaired patients. Interestingly, the
majority of studies assessing nerve conduction in COPD
show that polyneuropathy affects preferentially the
sensory nerves of the lower limbs.
Polyneuropathy has a profound impact on the somato-
sensory system and people with polyneuropathy show defi-
cits in postural control as assessed by single-leg stance,76
gait (i.e., speed, kinematics and efficiency),77 lower limb
muscle function (i.e., peak velocity and strength),78 in
addition to a high prevalence of falls.79,80 Unfortunately, to
date no studies have specifically examined the prevalence of
polyneuropathy in a large cohort of people with COPD.
Moreover, the impact that polyneuropathy may have on
proprioception, reaction time, muscle activation and
postural control in people with COPD is unknown.
Visual deficits
Visual deficits havebeenassociatedwith an increased risk for
falling in older adults.81,82 For example, in a large prospec-
tive cohort study with 2002 older women, Coleman et al.
reported that the odds of experiencing a fall were approxi-
mately two times greater for those with loss of vision.83 In
other studies, the relative fall risk in people with visual
deficits compared to people without visual problems has
been estimated to be 1.45; 95% CI: 1.08,1.94.84 Associations
between impaired vision and falls might be mediated by the
role that visual inputs, particularly stereopsis and contrast
sensitivity, play in the stabilization of posture.81,85 This is
especially relevant in older people who are more dependent
on vision to maintain a standing posture.86
There are no studies reporting on the prevalence of
visual impairments in people with COPD. Several studies,
however, have found strong dose-dependent associationsbetween inhaled corticosteroid use and risk of cata-
racts87e89 as well as associations between oral corticoste-
roids and risk of glaucoma.90 Cataracts and glaucoma
reduce visual acuity, impair postural control, and have
been associated with an increased rate of falls.91,92 Since
inhaled corticosteroids are frequently prescribed in people
with COPD,93 the deleterious effects these medications use
can have on visual function and falls should not be under-
estimated. Smoking has also been correlated with an
increased risk of cataracts, particularly nuclear cataracts.94
Although the associations of corticosteroids and smoking
with cataracts and glaucoma are well established, there are
no studies analyzing the prevalence of either corticosteroid
or smoking induced visual deficits in a large cohort of
patients with COPD. Similarly, there are no studies
exploring associations between visual deficits and risk for
falls in people with COPD. Likewise, the potential role that
visual deficits have as a risk factor for falls in people with
COPD is only theoretical (Table 1).
Nutritional depletion and malnutrition
Nutritional depletion, which is common among people with
COPD,95,96 is characterized by body weight loss, in partic-
ular, muscle mass.97 The loss of muscle mass in people with
COPD has been associated with increased mortality,98
impaired muscle function,99,100 reduced exercise
capacity101 and poorer HRQoL.102 Even though there are not
studies reporting on the association between nutritional
depletion and risk for falls, leg muscle mass assessed by
dual-energy X-ray absorptiometry (DEXA) has been found to
be significantly lower (p< 0.01) in a group older adults
fallers compared to non-fallers.56 The deleterious conse-
quences of muscle depletion on function and mobility are
well established.40
Malnutrition is not uncommon in people with COPD. For
example, recent studies have reported that people with
COPD show low levels of circulating vitamin D.103,104
Vitamin D deficiency is important because it has been
associated with an increased risk for falling.105 The physi-
ological mechanisms underlying this correlation are possibly
related to the role that vitamin D plays in muscle func-
tion.106 In support of this, vitamin D supplementation has
shown to be effective in improving neuromuscular function
and postural control in older adults.107,108 and higher
vitamin D serum levels (25-hydroxyvitamine D) have been
correlated with increased lung function in a large (14,091
participants) cohort study.109 Whether vitamin D supple-
mentation improves respiratory function or reduces the
incidence of falls in people with COPD is yet to be deter-
mined, however, the low levels of circulating vitamin D and
the high prevalence of osteoporosis among patients with
COPD110 provide some indication that vitamin D supple-
mentation might be beneficial. Although the effects that
nutritional depletion and malnutrition have on the risk for
falls in people with COPD are uncertain, the evidence of
decreased muscle mass and nutritional deficits in COPD is
strong. Due to the well established association between
muscle mass and strength,111 as well as the impact of
muscle weakness on the risk for falls,27 it is possible that
nutritional depletion may contribute as a risk factor for
falls in COPD (Table 1).
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The use of an assistive device has been associated with an
increased risk for falling (ORZ 2.6; 1.2e4.6).20 The reasons
why people who use an assistive device fall more frequently
are unclear and it is possible that the use of these devices
could simply reflect impaired mobility, gait and balance, all
of which have been associated with increased fall risk.20,68
The use of an assistive device may also reflect fear of
falling, which is thought to impact on the physical perfor-
mance and mobility of older adults.112 Some people with
COPD that are oxygen dependent use portable oxygen tanks
to reduce breathlessness. However, these devices have now
become so portable and small that they do not seem to
interfere with the normal mobility of these individuals. In
addition, some people with severe COPD use wheel-walkers
and scooters to facilitate mobility, however, the use of
these devices is not more frequent in this group than in
older adults. There are no studies indicating that the use of
any assistive device in people with COPD could increase the
risk for falling (Table 1).
Impaired activities of daily living (ADLs)
Impaired ADLs have been associated with an increased risk
for falling in older adults (ORZ 2.3; 1.5e3.1).20,23
However, the order of causation of impaired ADLs and falls
is uncertain. Impaired ADLs are normally accompanied by
reduced mobility and poor physical performance, both of
which have been associated with increased risk for falling in
older adults.113 On the other hand, injurious falls are
sometimes followed by a period of immobilization, which
has detrimental effects on mobility, physical conditioning
and ADLs. Numerous studies employing different quantifi-
cation methods have confirmed that people with COPD have
impaired ADLs compared to healthy individuals. For
example, Pitta et al. used triaxial accelerometers to eval-
uate physical activity levels in 50 people with moderate to
severe COPD (FEV1Z 43 18% predicted) compared to 25
healthy controls.114 Compared to the control group, people
with COPD showed significantly lower levels of physical
activity (i.e., lower walking/standing time and higher
sitting/lying time) and movement intensity (during
walking). Similar findings have been obtained in several
other studies using either motion sensors or physical
activity questionnaires.115,116 Therefore, impaired ADLs in
people with COPD are well established (Table 1).
Depression and cognitive impairments
Recent studies have reported that depression is associated
with the number of falls in older adults.23 Although
depression and falls share common risk factors (e.g.,
impaired ADLs and impaired cognitive function),117 the
underlying mechanisms governing this association and the
order of causation are unclear. A potential explanation
might be that the use of antidepressant medications can
have deleterious effects on the physical status of people
with depression.118 Others have suggested that depression
may result in inattention to potential environmental
hazards.20COPD has recently been associated with a number of
psychiatric disorders,119 including depression and
anxiety.120,121 Several studies have reported on the preva-
lence of depression and anxiety in COPD, which could
affect between 2e57% and 2e51% of these people respec-
tively.122,123 Compared to control subjects,12 this high
prevalence of depression may suggest that people with
COPD have an increased risk for falling (Table 1). However,
there are no studies assessing associations between
depression and fall occurrence in people with COPD.
Furthermore, although medications commonly prescribed
for anxiety disorders (e.g., benzodiazepines and neurolep-
tics) have been associated with an increased risk for
falls,118 the potential association between anxiety and falls
has not yet been determined.
Cognitive impairments have been identified as an
important factor of increased fall risk in older adults. For
example, a 2-year prospective study showed that people
with dementia fell four times per year,124 which is a much
higher rate than commonly reported rates from older
community-dwelling adults.125 Another prospective study
with 336 old adults (75 years) showed that people with
cognitive impairments fall 5 times more (ORZ 5; 95% CI:
1.8,13.7) than people without cognitive impairments.125
The major involvement of associative cortical areas in the
integration of sensory and executive tasks126 may explain
the link between reduced cognitive capacity and increased
risk for falls. For example, a recent cross-sectional study
found significantly increased postural sway and lower
performance of executive functions (i.e., set shifting,
updating and response inhibition) in people with mild
cognitive impairment compared with people without
cognitive deficits.127
Several studies have reported that cognitive impair-
ments are not uncommon among people with COPD, espe-
cially in those with hypoxemia and hypercapnia.128 For
example a clinical study showed that 42% of hypoxemic
people with COPD (PaO2 51 mmHg) had severe cognitive
impairments, assessed through neuropsychological tests,
compared with only 14% of controls.129 These seminal
findings have been recently confirmed with more advanced
brain imaging techniques. For example, compared to
healthy and non-hypoxemic people with COPD, hypoxemic
people with COPD have shown reduced brain perfusion in
both anterior and sub-cortical areas of the dominant
hemisphere evaluated through single photon emission
computed tomography (SPECT).130 More importantly, such
changes in brain perfusion have been correlated to poorer
performance in neuropsychological tests in people with
COPD.131 Even though these studies suggest that cognitive
impairment is not rare in people with COPD, the exact
prevalence of cognitive impairment and their effects on fall
risk in COPD is currently unknown (Table 1).
Medications
Numerous studies have shown that certain types of medi-
cations are associated with an increased frequency of falls
in older people. In a systematic review, Leipzig and
colleagues found that cardiac and psychotropic drugs
increased the risk for falls with ORs ranging from 0.9 to 1.6
and 1.5 to 1.7 respectively.132,133 Similar findings have been
1264 M. Roig et al.replicated in other studies investigating the action of
central nervous system medications (e.g., narcotics and
antidepressants) in the risk for falls and fractures in older
women.118 For example, Tinetti and colleagues found that
sedative medications (i.e., benzodiazepines, phenothia-
zines and antidepressants) significantly increased the risk
for falls in older people (ORZ 28.3; 95% CI: 3.4,239.4).125
The number of medications has also been independently
correlated to impaired postural control assessed by
a composite of balance measures (i.e., side by side
balance, sternal nudge, tandem stand, one leg standing
balance).134
Medications commonly used in the management of COPD
include: bronchodilators (anticholinergics, b2-agonists,
methylxanthines), oral and inhaled corticosteroids, and
theophylline. Other less frequent pharmacologic treat-
ments include: vaccines, mucolytics, antitussives, Alpha-1
antitrypsin augmentation therapy, antioxidants, immunor-
egulators, vasodilators, narcotics, and antibiotics in case of
acute infection.135 While some of these medications may
have adverse side effects including dizziness, postural
hypotension, altered vision and long-term cognitive
changes that might theoretically increase the risk for
falling,24 the frequency and severity of these side effects
and any impact they may have on fall risk in patients with
COPD is still to be elucidated.
Two types of medications commonly used in COPD
warrant special attention for their potential adverse
effects on fall risk: corticosteroids and psychotropics.
Corticosteroid use in people with COPD has been estimated
to be w61.5% and w8.3% for inhaled and oral corticoste-
roids respectively.93 In spite of their known benefits,136
these medications have several detrimental side effects
that can potentially increase the risk for falling. Side
effects of corticosteroid use include stereoid induced
myopathy, hyperglycemia, hypertension, loss of bone
mineral density, glaucoma and cataracts.137 Some of these
side effects have been specifically observed in people with
lung disease. For example, Nava et al. reported muscle
weakness after 5 days of treatment with high dosage
(12 mg kg1) of methylprednisolone in patients with acute
lung rejection.138 Although not all studies have observed
such decline in muscle function,139 the detrimental effects
of corticosteroids, in particular oral corticosteroids, on
both respiratory and peripheral muscle function in people
with COPD are well established.140
Long-term use of corticosteroids in people with COPD
has also been associated with metabolic disorders such as
osteoporosis and osteopenia110 and a subsequent increased
risk of bone fracture in some,141 but not all,142,143 studies.
The severity of side effects such as muscle weakness, risk of
fracture and visual deficits appears to be related to the
dose, duration, and type of administration (i.e., oral
corticosteroids produce more side effects).89,135,144,145
Differences in these parameters might well explain con-
flicting results among studies. Given the deleterious effects
that visual impairments,81,82 and muscle weakness,25,26
have on the risk for falling, the use of corticosteroids in
patients with COPD needs to be weighed against the
potential risks.145
Because people with COPD experience many psycholog-
ical effects such as depression, anxiety and sleepdisorders,119 the use of psychotropic medications including
antidepressants and benzodiazepines is conceivably high
among these patients. Anxyolitics, narcotics and antide-
pressants have been associated with an increased risk for
falling in several studies.16,118 The underlying mechanisms
explaining the association between the use of these medi-
cations and increased fall risk might be related to
commonly reported side effects such as dizziness, fatigue,
daytime sleepiness, slowed postural reflexes, postural
hypotension and impaired postural control.146 Since no
specific studies have quantified the exact prevalence of use
of these substances in people with COPD, the importance
that these medications may exert on their risk for falling
remains unknown (Table 1).
Precipitating factors
Syncope and postural orthostatic hypotension
Syncope has been defined as a transient, self-limited loss of
consciousness, usually leading to a fall.147 The multitude of
possible aetiologies and potential recall bias (e.g.,
retrograde amnesia is common after syncope) makes the
prevalence of syncope difficult to determine. However,
a one-year-prospective study including 711 older people (87
years), reported an incidence of 6% per year, with a two-
year prevalence and recurrence rates of 10% and 30%
respectively.148 Recently, syncope has been identified as
a potential risk factor for falls.23 The percentage of falls
related to syncope have been estimated to range between
0.5 and 3%, however, the existing overlap between falls and
syncope149 and the fact that syncope is excluded in most
studies of falls, suggest that this percentage might be
higher.30 There are no studies investigating syncope in
COPD, however, both conditions share some common
aspects that suggest that the risk of syncope in people with
COPD might be significant. The likelihood of syncope is
increased with cardiovascular diseases (i.e., coronary heart
disease and aortic stenosis) and the use of hypertensive
medication.150 Due to the multiple effects of smoking and
other shared predisposing factors (e.g., systemic inflam-
mation), the risk of cardiovascular disease (ORZ 2.4; 95%
CI: 1.9,3) and hypertension (ORZ 1.6; 95% CI: 1.3,1.9) in
people with COPD is high.151 Nevertheless, given that no
studies have examined the association between syncope
and COPD, whether there is an increased risk for falls due
to a transient loss of consciousness in people with COPD
needs to be investigated further (Table 2).
Postural orthostatic hypotension (POH) is clinically
defined as a fall in blood pressure of at least 20 mmHg
systolic or 10 mmHg diastolic when standing or during head-
up tilt testing.152 The prevalence of POH in older adults is
estimated to lie between the range of 5 and 30%.152 Age,
the use of some medications (e.g., antihypertensives,
diuretics, antidepressants) and some clinical conditions
(e.g., diabetes, Parkinson’s disease, autonomic disorders)
are contributing factors of POH.152 Transient dizziness after
changing posture, the most commonly reported symptom of
POH, is thought to increase the risk for falling, however, the
association between POH and fall occurrence remains
speculative.30 From our clinical experience, the prevalence
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Falls in patients with chronic obstructive pulmonary disease 1265of POH in people with COPD is possibly high. However, there
are no formal studies investigating POH in COPD and as
such, its potential implication in fall occurrence among
these patients cannot be determined (Table 2).
Exacerbations
An exacerbation is defined as ‘‘a sustained worsening of the
patient’s condition, from the stable state and beyond
normal day-to-day variations, necessitating a change in
regular medication in a patient with underlying COPD’’.153
The exact prevalence of exacerbations in people with COPD
is difficult to calculate because it varies substantially
depending on the severity of the disease as well as the prior
number of exacerbations.154 However, recent studies have
shown that people with severe and moderate COPD
(according to the classification of the Global Initiative for
Chronic Obstructive Lung Disease) might experience an
average of 3.43 and 2.63 exacerbations per year
respectively.155
Since exacerbations usually require hospitalization,
prolonged bed rest and aggressive pharmacological inter-
ventions (e.g., high doses of oral corticosteroids), muscle
atrophy and weakness associated with exacerbations are
likely. For example, Spruit et al.156 observed that quadri-
ceps peak torque was reduced in people with COPD
(FEV1Z 66 22% predicted) hospitalized due to an exac-
erbation, compared to a group of clinically stable COPD
patients (FEV1Z 86 16% predicted). More importantly,
peripheral muscle weakness was still apparent 3 months
after discharge from the hospital. Peripheral muscle
weakness could contribute to the reduced levels of physical
activity observed in people with COPD even one month
after exacerbations.157 Due to the negative effects of
exacerbations on muscle function and physical activity
levels, gait and balance deficits after exacerbations cannot
be discarded. Thus, an increased risk for falls secondary to
exacerbations is possible (Table 2).
Dyspnea
Dyspnea is the most common activity-limiting symptom of
COPD. Because the level of dyspnea is strongly correlated
to the intensity of the activity performed, people with
COPD tend to progressively reduce physical activity and
ADLs. This further contributes to overall physical decondi-
tioning, which increases the level of inactivity and, in the
long term, social isolation.158 There are no studies
analyzing the potential impact of dyspnea on falls occur-
rence but it seems unlikely that dyspnea could contribute
as a precipitating (i.e., acute) factor for falls in people with
COPD. Paradoxically, dyspnea leads people with COPD to
adopt a much more sedentary lifestyle that reduces
mobility and that could eventually ‘‘protect’’ these
patients from falling. However, the long-term conse-
quences of dyspnea and its detrimental impact on physical
activity and further deconditioning in COPD are well
established.117 Although dyspnea as a precipitating factor
does not appear to increase the risk for falling, the long-
term effects of dyspnea have important repercussions in
the overall physical status of people with COPD that can
increase fall risk (Table 2).
1266 M. Roig et al.Summary
The results of this review suggest that people with COPD
may have an increased risk for falling compared to their
healthy peers. Most of the risk factors for falls identified in
older people are common in people with COPD. There is
evidence that lower limb muscle weakness and impaired
activities of daily living are well-established risk factors for
falls in people with COPD. Other intrinsic factors such as
gait and balance deficits, nutritional depletion, malnutri-
tion, depression, cognitive impairments and medications
are possible risk factors that need to be confirmed with
further research. Due to the lack of studies, the potential
implication of visual deficits on fall occurrence in people
with COPD is only theoretical. There is no evidence to
suggest that people with COPD may have an increased risk
for falls associated with the use of an assistive device.
While the role that precipitating factors such as syncope
and postural hypotension may have on fall occurrence in
COPD is unclear, the long-term effects of dyspnea and
exacerbations on limited mobility and progressive physical
deterioration might theoretically increase the risk for falls.
In summary, we have used a physiological approach to
present a theoretical framework of potential risk factors
for falls in COPD (Fig. 1). Even though our results suggest
that fall risk in people with COPD may be high, the lack of
epidemiological studies assessing the prevalence of falls
and the scarcity of clinical trials analyzing specific risk
factors for falls in people with COPD indicates that the
conclusions of this study must be tempered. Further
research is needed to determine the prevalence of falls and
specific risk factors for falls in people living with COPD. In
the meantime, we expect that the proposed framework
may provide a basis to generate relevant research questions
regarding the risk for falls among people with COPD.
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